C-reactive protein as a marker of metainflammation in chronic heart failure and sarcopenic obesity

   Introduction. Currently, meta-inflammation is considered a factor in the initiation and development of chronic heart failure (CHF) with preserved ejection fraction. A common comorbid condition in such patients is sarcopenic obesity (SO). The study of the level of CRP, as a marker of metaflammation, in patients with CHF and SO is a promising area for clinical medicine.

   The aim of the research. Determination of the level of C-reactive protein as a marker of meta-inflammation in patients with chronic heart failure and sarcopenic obesity.

   Materials and methods. A total of 298 patients underwent a SARC-F (SARCOPENIA-FAST) questionnaire, hand dynamometry, bioimpedance, and a 4-m walking speed test. Clinical status scales (SHOCKS) and a 6-min walking test (6MWT), approved by clinical guidelines and approved by the Ministry of Health of the Russian Federation, were used. The ejection fraction was studied, and the level of hsCRP was determined by the ELISA method (Cloud-clone, China). The patients were divided into 5 groups depending on their body composition — the presence of obesity and sarcopenia. Statistical processing was performed using the IBSS Statistics 25.0 package.

   Results. The level of hsCRP in the group of patients with sarcopenic obesity significantly differed from the indicator in the groups of patients without sarcopenia, without obesity and without disorders of body composition. The values were comparable in the groups of patients with sarcopenic obesity and those with reduced body weight and sarcopenia. An increase in the hsCRP marker was also found in the group of patients with sarcopenic obesity, compared with the indicators in the groups of patients with obesity or sarcopenia only. The functional status of the patients was lower, which highlights the contribution of metaflammation during the disease course.

   Conclusion. An increase in the level of the hsCRP marker in patients with sarcopenic obesity reflects a more severe course of CHF.

1. Ambroselli D, Masciulli F, Romano E, et al. New Advances in Metabolic Syndrome, from Prevention to Treatment: The Role of Diet and Food. Nutrients. 2023;15(3):640. doi: 10.3390/nu15030640.

2. Ely BR, Clayton ZS, McCurdy CE, et al. Meta-inflammation and cardiometabolic disease in obesity: Can heat therapy help? Temperature (Austin). 2017;5(1):9-21. doi: 10.1080/23328940.2017.1384089.

3. Yao J, Wu D, Qiu Y. Adipose tissue macrophage in obesity-associated metabolic diseases. Frontiers in Immunology. 2022;(13):977485. doi: 10.3389/fimmu.2022.977485.

4. Vavilova TP, Pleten' AP, Mikheev RK. Biological role of adipokines and their association with morbid conditions. Voprosy Pitaniia. 2017;86(2):5-13. (In Russ.) doi: 10.24411/0042-8833-2017-00028.

5. Russo S, Kwiatkowski M, Govorukhina N, et al. Meta-Inflammation and Metabolic Reprogramming of Macrophages in Diabetes and Obesity: The Importance of Metabolites. Frontiers in Immunology. 2021;(12):746151. doi: 10.3389/fimmu.2021.746151.

6. Drapkina ОМ, Skripnikova IA, Yaralieva EK, Myasnikov RP. Body composition in patients with chronic heart failure. Cardiovascular Therapy and Prevention. 2022;21(12):34-51. (In Russ.)] doi: 10.15829/1728-8800-2022-3451.

7. Lena A, Anker MS, Springer J. Muscle Wasting and Sarcopenia in Heart Failure-The Current State of Science. International Journal of Molecular Sciences. 2020;21(18):6549. doi: 10.3390/ijms21186549.

8. Drapkina OM, Budnevsky AV, Ovsyannikov ES, et al. Sarcopenic obesity: patterns and paradoxes. Preventive medicine. 2021;24(1):73-81. (In Russ.) doi: 10.17116/profmed20212401173.

9. Donini LM, Busetto L, Bischoff SC, et al. Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement. Obesity Facts. 2022;(15):321-35. doi: 10.1159/000521241.

10. Pacifico J, Geerlings MAJ, Reijnierse EM, et al. Prevalence of sarcopenia as a comorbid disease : a systematic review and meta-analysis. Experimental Gerontology. 2020;(131):110801. doi: 10.1016/j.exger.2019.110801.

11. Mikaelyan AA, Varaeva YuR, Liskova YuV, et al. Sarcopenia and Chronic Heart Failure. Part 1. General Medicine. 2023;2:51-6. (In Russ.) doi: 10.24412/2071-5315-2023-12879

12. Burger PM, Koudstaal S, Mosterd A, et al; UCC-SMART study group. C-Reactive Protein and Risk of Incident Heart Failure in Patients With Cardiovascular Disease. Journal of the American College of Cardiology. 2023;82(5):414-426. doi: 10.1016/j.jacc.2023.05.035. PMID: 37495278

13. Berns SA, Sheptulina AF, Mamutova EM, et al. Sarcopenic obesity: epidemiology, pathogenesis and diagnostic criteria. Cardiovascular Therapy and Prevention. 2023;22(6):3576. (In Russ.) doi: 10.15829/1728-8800-2023-3576.

14. Safonova YuA, Toroptsova NV. The clinician. 2022:16(2):40-7. (In Russ.) doi: 10.17650/1818-8338-2022-16-2-K661.

15. DuBrock HM, AbouEzzeddine OF, Redfield MM. High-sensitivity C-reactive protein in heart failure with preserved ejection fraction. PloS Оne. 2018;13(8):e0201836. doi: 10.1371/journal.pone.0201836.

16. Pellicori P, Zhang J, Cuthbert J. High-sensitivity C-reactive protein in chronic heart failure: patient characteristics, phenotypes, and mode of death. Cardiovascular Research. 2020;116(1):91-100. doi: 10.1093/cvr/cvz198.

17. Khazova EV, Bulashova OV, Amirov NB. Is it necessary to determine highly sensitive C-reactive protein in patients with chronic heart failure: clinical and prognostic aspects. Bulletin of contemporary clinical medicine. 2022;15(4):54-9. (In Russ.) doi: 10.33619/2414-2948/89.

18. Fyodorova TA, Ivanova YeA, Semenenko NA, et al. Clinical and Laboratory Aspects of Chronic Heart Failure in Patients with Metabolic Syndrome. Effective pharmacotherapy. 2019;15(20):10-6. (In Russ.) doi: 10.33978/2307-3586-2019-15-20-10-16.

19. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circulation Research. 2005;96(9):939-49. doi: 10.1161/01.RES.0000163635.62927.34.

20. Curcio F, Testa G, Liguori I, et al. Sarcopenia and heart failure. Nutrients. 2020;12(1):211. doi: 10.3390/nu12010211.